US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid tumours.
Based on the firm’s linkerless gene trimer technology, GITRL-Fc is an investigational immuno-oncology agent being developed to utilise the natural trimeric ligand to inhibit T-regulatory cells and stimulate T-effector cells for altering the tumour microenvironment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The therapeutic candidate is designed to directly agonise the glucocorticoid-induced TNFR-related protein (GITR) T-cell activation receptor, which leads to decreased T-regulatory cells and increased T-effector cells.
Set to be conducted at five sites in the country, the open-label Phase Ia trial will evaluate the safety and tolerability of increasing GITRL-Fc doses in 30 advanced or metastatic solid tumour patients.
OncoMed Pharmaceuticals clinical research and development senior vice-president Robert Stagg said: "GITRL-Fc is a fusion protein consisting of the fully human natural trimer GITR ligand linked to an Fc.
“Pre-clinical experiments have suggested that this agent may be a more potent agonist of the GITR trimer receptor than bivalent agonist antibodies.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial’s secondary objectives are pharmacokinetics, immunogenicity and anti-tumour efficacy, while pharmacodynamic and potential predictive biomarkers of changes in immune system activation will also be investigated.
GITRL-Fc will be assessed as a monotherapy, given every two weeks at escalating dose levels.
Upon determination of a maximum-tolerated dose, an expansion cohort will be initiated for patients with specific types of tumours.
